MetaBlok™

Potential Treatment for Lung Inflammation

Metablok is our lead drug candidate for treating inflammation in the lungs, liver and kidneys. 

Arch Biopartners is now focused on beginning a Phase II Trial to investigate Metablok’s efficacy in treating inflammation-related lung injury in COVID-19 infected patients. In the worst cases of COVID-19 infection, fatalities are often...

Arch Biopartners Safely Completes Expanded Dosing of METABLOK in Phase I Human Trial and Begins Focus on Phase II Trial

TORONTO, March 17, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final eight healthy volunteers in its Phase I human trial...

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver

Authors

Saurav Roy Choudhury, Liane Babes, Jennifer J. Rahn, Bo-Young Ahn, Kimberly-Ann R. Goring, Jennifer C. King, Arthur Lau, Björn Petri, Xiaoguang Hao, Andrew K. Chojnacki, Ajitha Thanabalasuriar, Erin F. McAvoy, Sébastien Tabariès, Christoph...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is currently a Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular Biology. He is a former Canada Research Chair...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual...

    News &
    Publications

    Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

    TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates...

    Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation

    TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates...

    Stock information

    Arch Biopartners trades as ARCH:TSXV in Canada, and ACHFF:OTCBB in the United States.

    Management and Board of Directors

    Investor Relations and Investor Information